Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
2
Issued Date
2022-01-01
Resource Type
ISSN
21645515
eISSN
2164554X
Scopus ID
2-s2.0-85124189767
Pubmed ID
35103548
Journal Title
Human Vaccines and Immunotherapeutics
Volume
18
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Human Vaccines and Immunotherapeutics Vol.18 No.1 (2022)
Suggested Citation
Hattasingh W., Chanthavanich P., Sirivichayakul C., Arunsodsai W., Surangsrirat S., Srisuwannaporn T., Kaewma B., Yoksan S., Limkittikul K., Yang J., Mao Y. Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Human Vaccines and Immunotherapeutics Vol.18 No.1 (2022). doi:10.1080/21645515.2022.2028513 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85059
Title
Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
Other Contributor(s)
Abstract
Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vaccine trial, an inactivated chromatographically purified Japanese encephalitis Vero cell vaccine (CVI-JE; JEVACTM) was safe and immunogenic in 152 Thai children aged 1–3 years receiving a 2-dose primary immunization and booster dose 1 year later. We conducted a 5-year follow-up assessment of the persistence of the immune response the 144 children remaining in this cohort after first booster dose. Immunity was assessed by 50% plaque reduction neutralization test annually for up to 5 years post-booster. Seroprotection rates (95%CI) decreased from 100% (97.1–100) at 1 year post-booster to 93% (85.0–98.3) at 5 years post-booster. No serious vaccine-related adverse events or Japanese encephalitis infections were reported. A 2-dose primary immunization and booster 1 year later with CVI-JE provided long-lasting immunity in the majority of children.